Standardized evidence-based approach for assessment of oncogenic and clinical significance of NTRK fusions.


Journal

Cancer genetics
ISSN: 2210-7762
Titre abrégé: Cancer Genet
Pays: United States
ID NLM: 101539150

Informations de publication

Date de publication:
06 2022
Historique:
received: 18 10 2021
revised: 13 02 2022
accepted: 07 03 2022
pubmed: 3 4 2022
medline: 26 5 2022
entrez: 2 4 2022
Statut: ppublish

Résumé

Gene fusions involving the neurotrophic receptor tyrosine kinase genes NTRK1, NTRK2, and NTRK3, are well established oncogenic drivers in a broad range of pediatric and adult tumors. These fusions are also important actionable markers, predicting often dramatic response to FDA approved kinase inhibitors. Accurate interpretation of the clinical significance of NTRK fusions is a high priority for diagnostic laboratories, but remains challenging and time consuming given the rapid pace of new data accumulation, the diversity of fusion partners and tumor types, and heterogeneous and incomplete information in variant databases and knowledgebases. The ClinGen NTRK Fusions Somatic Cancer Variant Curation Expert Panel (SC-VCEP) was formed to systematically address these challenges and create an expert-curated resource to support clinicians, researchers, patients and their families in making accurate interpretations and informed treatment decisions for NTRK fusion-driven tumors. We describe a system for NTRK fusion interpretation (including compilation of key elements and annotations) developed by the NTRK fusions SC-VCEP. We illustrate this stepwise process on examples of LMNA::NTRK1 and KANK1::NTRK2 fusions. Finally, we provide detailed analysis of current representation of NTRK fusions in public fusion databases and the CIViC knowledgebase, performed by the NTRK fusions SC-VCEP to determine existing gaps and prioritize future curation activities.

Identifiants

pubmed: 35366592
pii: S2210-7762(22)00024-2
doi: 10.1016/j.cancergen.2022.03.001
pmc: PMC9252326
mid: NIHMS1802977
pii:
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Biomarkers, Tumor 0
Cytoskeletal Proteins 0
KANK1 protein, human 0
Oncogene Proteins, Fusion 0
Receptor, trkA EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

50-59

Subventions

Organisme : NHGRI NIH HHS
ID : U24 HG009649
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA237719
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24 HG009650
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24 HG006834
Pays : United States
Organisme : NHGRI NIH HHS
ID : R00 HG007940
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Références

Sci Rep. 2016 Feb 10;6:21597
pubmed: 26862001
J Biol Chem. 2004 Feb 20;279(8):6225-34
pubmed: 14668342
Cold Spring Harb Mol Case Stud. 2019 Oct 23;5(5):
pubmed: 31645350
Nucleic Acids Res. 2020 Jan 8;48(D1):D817-D824
pubmed: 31680157
Nat Genet. 2017 Jan 31;49(2):170-174
pubmed: 28138153
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii16-viii22
pubmed: 31738428
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
Sci Rep. 2019 Dec 11;9(1):18789
pubmed: 31827189
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
J Neurosci. 2003 May 15;23(10):4208-18
pubmed: 12764109
Nucleic Acids Res. 2019 Jan 8;47(D1):D994-D1004
pubmed: 30407583
Cancer Discov. 2017 Apr;7(4):400-409
pubmed: 28183697
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Ann Transl Med. 2019 Apr;7(7):148
pubmed: 31157269
J Mol Diagn. 2019 Jul;21(4):553-571
pubmed: 31075511
J Pathol Clin Res. 2020 Apr;6(2):107-112
pubmed: 32022484
Nucleic Acids Res. 2018 Jan 4;46(D1):D1144-D1149
pubmed: 29099951
N Engl J Med. 2015 Jun 4;372(23):2235-42
pubmed: 26014595
Neuropathol Appl Neurobiol. 2019 Feb;45(2):174-178
pubmed: 29804288
Blood. 2020 Jun 11;135(24):2159-2170
pubmed: 32315394
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Nucleic Acids Res. 2020 Jan 8;48(D1):D682-D688
pubmed: 31691826
J Cutan Pathol. 2020 Jan;47(1):70-75
pubmed: 31437301
Genome Med. 2019 Nov 29;11(1):76
pubmed: 31779674
N Engl J Med. 2017 Oct 12;377(15):1409-1412
pubmed: 29020592
Hum Mutat. 2018 Nov;39(11):1721-1732
pubmed: 30311370
J Natl Cancer Inst. 2015 Nov 12;108(1):
pubmed: 26563355
Nucleic Acids Res. 2016 Mar 18;44(5):e47
pubmed: 26582927

Auteurs

Jason Saliba (J)

Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO United States.

Alanna J Church (AJ)

Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.

Shruti Rao (S)

Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington D.C., United States.

Arpad Danos (A)

Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO United States.

Larissa V Furtado (LV)

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, United States.

Theodore Laetsch (T)

Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

Liying Zhang (L)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, United States.

Valentina Nardi (V)

Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.

Wan-Hsin Lin (WH)

Department of Cancer Biology, Mayo Clinic Florida, Jacksonville, FL, United States.

Deborah I Ritter (DI)

Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, United States.

Subha Madhavan (S)

Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington D.C., United States; AstraZeneca, Cambridge, United Kingdom.

Marilyn M Li (MM)

Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.

Obi L Griffith (OL)

Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO United States.

Malachi Griffith (M)

Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO United States.

Gordana Raca (G)

Department of Pathology and Laboratory Medicine, Children's Hospital of Los Angeles, Los Angeles, CA, United States.

Angshumoy Roy (A)

Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, United States; Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, United States; Department of Pathology, Texas Children's Hospital, Houston, TX, United States. Electronic address: aroy@bcm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH